Association of androgenic-anabolic steroid therapy with development of hepatocellular carcinoma.
D000293:Adolescent; D000328:Adult; D045930:Anabolic Agents / Q000009:adverse effects; D000728:Androgens / Q000009:adverse effects*; D000741:Anemia, Aplastic / Q000188:drug therapy; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced* / Q000473:pathology; D002675:Child, Preschool; D005198:Fanconi Syndrome / Q000188:drug therapy; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D008696:Methandrostenolone / Q000009:adverse effects / Q000627:therapeutic use; D008777:Methyltestosterone / Q000009:adverse effects / Q000627:therapeutic use; D010110:Oxymetholone / Q000009:adverse effects / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011877:Radionuclide Imaging; D013739:Testosterone / Q000009:adverse effects / Q000627:therapeutic use
D045930:Anabolic Agents; D000728:Androgens; D013739:Testosterone; D008696:Methandrostenolone; D010110:Oxymetholone; D008777:Methyltestosterone; D011241:Prednisone